{"url_path":"/sec/inkt/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-226804-index.html","accession_number":"0001193125-26-226804","cik":"0001840229","ticker":"INKT","issuer_name":"MiNK Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-226804-index.html","primary_entity_key":"0001840229","primary_entity_name":"MiNK Therapeutics, Inc."},"word_count":95,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDisclosure in lieu of reporting on a Current Report on Form 8-K.\n\nDeparture of Principal Accounting Officer\n\nOn May 12, 2026, Austin Charette, Principal Accounting Officer of the Company, informed the Company he will be resigning effective May 29, 2026.\n\nInsider trading arrangements and policies\n\nTrading Plans of Our Directors and Officers\n\nDuring the quarter ended March 31, 2026, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.\n\n \n\n19"}